Summary

Oncology Based In-vivo CRO Market Growth & Trends

The global oncology based in-vivo CRO market is expected to reach USD 1.9 billion by 2028, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 8.2% from 2021 to 2028. The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.

Furthermore, the pressure from the increasing competition due to patent expirations, rapid growth of generics, and introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth over the forecast period.

Another factor propelling growth is the increasing incidence of cancer, and high failure rate of existing treatment options. According to statistics published by the World Health Organization (WHO), approximately 8.2 million deaths are recorded each year from cancer, which accounts for 13.0% of deaths worldwide.

Oncology Based In-vivo CRO Market Report Highlights

• Based on indication, solid tumors are expected to dominate the market as of 2016. Furthermore, it is anticipated to grow at the fastest CAGR owing to the factors such as growing incidence rate, augmenting research for tumors in organs such as breast, and liver, and technological advancement offered by key industry players.

• Solid tumors are analyzed by means of models such as xenograft, Patient Derived Xenografts (PDX), and syngeneic. The PDX models are expected to witness lucrative growth over the forecast period and capture over 40.0% of the market share by 2025.

• Geographic expansion into Asia Pacific countries by well-established players is anticipated to promote the fastest growth for the region. India is one the most lucrative country owing to presence of service tax exemption and venture capital-based funding for CROs.

• A few of the industry players for the oncology based in-vivo CRO market are The Jackson Laboratory, Covance, Taconic Biosciences, Charles River Laboratory, EVOTEC, Wuxi AppTec, and ICON Plc.

• A common trend observed is the rising partnerships among CROs to offer bundled packages of services to sponsors. For instance, In May 2017, CRL International, Inc. announced their partnership with OcellO, established in Netherlands. According to this partnership, CRL would be utilizing the latter’s PDX model capabilities in order to expand its oncology-based drug discovery service portfolio.

ページTOPに戻る

Table of Contents

Table of Content

Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.1.1 Regional Scope
1.1.2 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Oncology Based In-vivo CRO Market: Variables, Trends, & Scope
3.1 Segment Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Accelerating the time to market
3.3.1.2 Economic efficiency
3.3.1.3 Increasing mergers and collaborations
3.3.1.4 Increasing outsourcing of R&D Activities
3.3.2 Market Restraint Analysis
3.3.2.1 Quality issues with CRO
3.3.2.2 Presence of suitable alternative
3.4 Oncology In-vivo CRO Market Analysis Tools
3.4.1 Porter’s Five Forces Analysis
3.4.2 PESTEL Analysis
Chapter 4 Oncology Based in-vivo CRO Market: Indication Estimates & Trend Analysis
4.1 Oncology Based in-vivo CRO Market: Indication Movement Analysis
4.2 Blood cancer
4.2.1 Blood cancer market estimates and forecasts, 2016 - 2028 (USD Million)
4.2.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2016 - 2028 (USD Million)
4.2.1.2 PDX based solid tumor market estimates and forecasts, 2016 - 2028 (USD Million)
4.2.1.3 Xenograft based solid tumor market estimates and forecasts, 2016 - 2028 (USD Million)
4.3 Solid tumors
4.3.1 Solid tumors market estimates and forecasts, 2016 - 2028 (USD Million)
4.3.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2016 - 2028 (USD Million)
4.3.1.2 PDX based solid tumor market estimates and forecasts, 2016 - 2028 (USD Million)
4.3.1.3 Xenograft based solid tumor market estimates and forecasts, 2016 - 2028 (USD Million)
4.4 Others
4.4.1 Other market estimates and forecasts, 2016 - 2028 (USD Million)
4.4.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2016 - 2028 (USD Million)
4.4.1.2 PDX based solid tumor market estimates and forecasts, 2016 - 2028 (USD Million)
4.4.1.3 Xenograft based solid tumor market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 5 Oncology Based in-vivo CRO Market: Regional Estimates & Trend Analysis, by Indication
5.1 Oncology Based in-vivo CRO Market Share by Region, 2020 & 2028
5.2 North America
5.2.1 North America oncology based in-vivo CRO market estimates and forecasts, 2016 - 2028
5.2.2 U.S.
5.2.2.1 U.S. oncology based in-vivo CRO market estimates and forecasts, by indication, 2016 - 2028 (USD Million)
5.2.3 Canada
5.2.3.1 Canada oncology based in-vivo CRO market estimates and forecasts, by indication, 2016 - 2028 (USD Million)
5.3 Europe
5.3.1 Europe oncology based in-vivo CRO market estimates and forecasts, 2016 - 2028
5.3.2 U.K.
5.3.2.1 U.K. oncology based in-vivo CRO market estimates and forecasts, by indication, 2016 - 2028 (USD Million)
5.3.3 Germany
5.3.3.1 Germany oncology based in-vivo CRO market estimates and forecasts, by indication, 2016 - 2028 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific oncology based in-vivo CRO market estimates and forecasts, 2016 - 2028
5.4.2 Japan
5.4.2.1 Japan oncology based in-vivo CRO market estimates and forecasts, by indication, 2016 - 2028 (USD Million)
5.4.3 China
5.4.3.1 China oncology based in-vivo CRO market estimates and forecasts, by indication, 2016 - 2028 (USD Million)
5.5 Latin America
5.5.1 Latin America oncology based in-vivo CRO market estimates and forecasts, 2016 - 2028
5.5.2 Brazil
5.5.2.1 Brazil oncology based in-vivo CRO market estimates and forecasts, by indication, 2016 - 2028 (USD Million)
5.5.3 Argentina
5.5.3.1 Argentina oncology based in-vivo CRO market estimates and forecasts, by indication, 2016 - 2028 (USD Million)
5.6 MEA
5.6.1 MEA oncology based in-vivo CRO market estimates and forecasts, 2016 - 2028
5.6.2 South Africa
5.6.2.1 South Africa oncology based in-vivo CRO market estimates and forecasts, by indication, 2016 - 2028 (USD Million)
5.6.3 Saudi Arabia
5.6.3.1 Saudi Arabia oncology based in-vivo CRO market estimates and forecasts, by indication, 2016 - 2028 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Company Profiles
6.2.1 Charles River Laboratory (CRL)
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Strategic initiatives
6.2.2 ICON Plc
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Strategic initiatives
6.2.3 Covance
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Service benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Eurofins Scientific
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Product benchmarking
6.2.4.4 Strategic initiatives
6.2.5 Taconic Biosciences
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.4 Product benchmarking
6.2.5.5 Strategic initiatives
6.2.6 Crown Bioscience
6.2.6.1 Company overview
6.2.6.2 Financial performance
6.2.6.3 Product benchmarking
6.2.6.4 Strategic initiatives
6.2.7 Toxikon, Inc.
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Product benchmarking
6.2.7.4 Strategic initiatives
6.2.8 WuXi AppTec
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.4 Product benchmarking
6.2.8.5 Strategic Initiatives
6.2.9 EVOTEC
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Product benchmarking
6.2.9.4 Strategic initiatives
6.2.10 The Jackson Laboratory
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.4 Product benchmarking
6.2.10.5 Strategic initiatives



List of Tables

Table 1 Global Oncology based in-vivo CRO market, by Region, 2016 - 2028 (USD Million)
Table 2 Global Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 3 Global Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 4 Global Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 5 Global Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 6 North America Oncology based in-vivo CRO market, by Country, 2016 - 2028 (USD Million)
Table 7 North America Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 8 North America Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 9 North America Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 10 North America Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 11 U.S. Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 12 U.S. Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 13 U.S. Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 14 U.S. Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 15 Canada Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 16 Canada Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 17 Canada Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 18 Canada Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 19 Europe Oncology based in-vivo CRO market, by Country, 2016 - 2028 (USD Million)
Table 20 Europe Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 21 Europe Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 22 Europe Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 23 Europe Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 24 U.K. Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 25 U.K. Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 26 U.K. Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 27 U.K. Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 28 Germany Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 29 Germany Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 30 Germany Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 31 Germany Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 32 Asia Pacific Oncology based in-vivo CRO market, by Country, 2016 - 2028 (USD Million)
Table 33 Asia Pacific Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 34 Asia Pacific Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 35 Asia Pacific Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 36 Asia Pacific Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 37 Japan Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 38 Japan Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 39 Japan Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 40 Japan Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 41 China Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 42 China Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 43 China Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 44 China Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 45 Latin America Oncology based in-vivo CRO market, by Country, 2016 - 2028 (USD Million)
Table 46 Latin America Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 47 Latin America Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 48 Latin America Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 49 Latin America Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 50 Brazil Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 51 Brazil Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 52 Brazil Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 53 Brazil Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 54 Argentina Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 55 Argentina Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 56 Argentina Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 57 Argentina Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 58 MEA Oncology based in-vivo CRO market, by Country, 2016 - 2028 (USD Million)
Table 59 MEA Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 60 MEA Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 61 MEA Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 62 MEA Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 63 South Africa Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 64 South Africa Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 65 South Africa Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 66 South Africa Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 67 Saudi Arabia Oncology based In-vivo CRO Market, by Indication, 2016 - 2028 (USD Million)
Table 68 Saudi Arabia Solid Tumor based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 69 Saudi Arabia Blood Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)
Table 70 Saudi Arabia Other Cancer based In-vivo CRO Market, by Model, 2016 - 2028 (USD Million)


List of Figures

Fig. 1 Market summary, 2020 (USD Million)
Fig. 2 Market trends & outlook
Fig. 3 Market segmentation & scope
Fig. 4 Market driver relevance analysis (Current & future impact)
Fig. 5 Pharmaceutical R&D spending, 2007 - 2012 (USD Billion)
Fig. 6 Market restraint relevance analysis (Current & future impact)
Fig. 7 Penetration & growth prospect mapping
Fig. 8 SWOT Analysis, By Factor (political & legal, economic and social)
Fig. 9 Porter’s Five Forces Analysis
Fig. 10 Oncology based in-vivo CRO market indication outlook key takeaways
Fig. 11 Oncology based in-vivo CRO market: Indication movement analysis
Fig. 12 Global blood cancer market, 2016 - 2028 (USD Million)
Fig. 13 Global syngeneic model based blood cancer market, 2016 - 2028 (USD Million)
Fig. 14 Global PDX model based blood cancer market, 2016 - 2028 (USD Million)
Fig. 15 Global xenograft based blood cancer market, 2016 - 2028 (USD Million)
Fig. 16 Global solid tumor market, 2016 - 2028 (USD Million)
Fig. 17 Global syngeneic model based solid tumor market, 2016 - 2028 (USD Million)
Fig. 18 Global PDX model based solid tumor market, 2016 - 2028 (USD Million)
Fig. 19 Global xenograft based solid tumor market, 2016 - 2028 (USD Million)
Fig. 20 Global other cancers market, 2016 - 2028 (USD Million)
Fig. 21 Global syngeneic model based other cancers market, 2016 - 2028 (USD Million)
Fig. 22 Global PDX model based other cancers market, 2016 - 2028 (USD Million)
Fig. 23 Global xenograft based other cancers market, 2016 - 2028 (USD Million)
Fig. 24 Regional market place: Key takeaways
Fig. 25 Regional outlook, 2020& 2028
Fig. 26 North America oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 27 U.S. oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 28 Canada oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 29 Europe in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 30 U.K. oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 31 Germany oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 32 Asia Pacific oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 33 Japan oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 34 China oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 35 Latin America oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 36 Brazil oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 37 Argentina oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 38 MEA oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 39 South Africa oncology based in-vivo CRO market, 2016 - 2028 (USD Million)
Fig. 40 Saudi Arabia oncology based in-vivo CRO market, 2016 - 2028 (USD Million)